Downregulation of interleukin 36γ and its cleaver cathepsin G following treatment with narrow-band ultraviolet B phototherapy in psoriasis vulgaris

References

• Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Furue M, Kadono T. Psoriasis: behind the scenes. J Dermatol. 2016;43(1):4–8.
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135(1):1–8.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12):1664–1675.
   PubMed Web of Science ®Google Scholar
• Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204(11):2603–2614.
   PubMed Web of Science ®Google Scholar
• Debets R, Timans JC, Homey B, et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol. 2001;167(3):1440–1446.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Guzman AM, et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol. 2011;186(4):2613–2622.
   PubMed Web of Science ®Google Scholar
• Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004;279(14):13677–13688.
   PubMed Web of Science ®Google Scholar
• Towne J, Sims J. IL-36 in psoriasis. Curr Opin Pharmacol. 2012;12(4):486–490.
   PubMed Web of Science ®Google Scholar
• D'Erme AM, Wilsmann-Theis D, Wagenpfeil J, et al. IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol. 2015;135(4):1025–1032.
   PubMed Web of Science ®Google Scholar
• Sullivan GP, Henry CM, Clancy DM, et al. Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases. Cell Death Dis. 2018;9(3):378.
   PubMedGoogle Scholar
• Guo J, Tu J, Hu Y, et al. Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis. Drug Des Devel Ther. 2019;13:581–588.
   PubMed Web of Science ®Google Scholar
• Kotb IS, Lewis BJ, Barker RN, et al. Differential effects of phototherapy, adalimumab and betamethasone-calcipotriol on effector and regulatory T cells in psoriasis. Br J Dermatol. 2018;179(1):127–135.
   PubMed Web of Science ®Google Scholar
• Wallace AB. The exposure treatment of burns. Lancet. 1951;1(6653):501–504.
   PubMedGoogle Scholar
• Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica . 1978;157(4):238–244.
   PubMedGoogle Scholar
• Tsukamoto T, Fukami H, Yamanaka S, et al. Hexosaminidase-altered aberrant crypts, carrying decreased hexosaminidase α and β subunit mRNAs, in Colon of 1,2-dimethylhydrazine-treated rats. Japanese J Cancer Res. 2001;92(2):109–118.
   PubMedGoogle Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432–437.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109–120.
   PubMed Web of Science ®Google Scholar
• Körber A, Mössner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis. J Invest Dermatol. 2013;133(11):2634–2637.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514–2521.
   PubMed Web of Science ®Google Scholar
• Boutet MA, Bart G, Penhoat M, et al. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol. 2016;184(2):159–173.
   PubMed Web of Science ®Google Scholar
• Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Sci Rep. 2017;7(1):15631.
   PubMedGoogle Scholar
• Wang W, Yu X, Wu C, et al. Il-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis. Int J Med Sci. 2017;14(10):1002–1007.
   PubMed Web of Science ®Google Scholar
• Foster AM, Baliwag J, Chen CS, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192(12):6053–6061.
   PubMed Web of Science ®Google Scholar
• Li N, Yamasaki K, Saito R, et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J Immunol. 2014;193(10):5140–5148.
   PubMed Web of Science ®Google Scholar
• Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286(49):42594–42602.
   PubMed Web of Science ®Google Scholar
• Abdou AG, Maraee AH, Sharaf A, et al. Up-regulation of notch-1 in psoriasis: an immunohistochemical study. Ann Diagn Pathol. 2012;16(3):177–184.
   PubMed Web of Science ®Google Scholar
• Kawada A, Hara K, Kominami E, et al. Processing of cathepsins L, B and D in psoriatic epidermis. Arch Dermatol Res. 1997;289(2):87–93.
   PubMed Web of Science ®Google Scholar
• Breuckmann F, von Kobyletzki G, Avermaete A, et al. Modulation of cathepsin G expression in severe atopic dermatitis following medium-dose UVA1 phototherapy. BMC Dermatol. 2002;2:12.
   PubMedGoogle Scholar
• Johnson-Huang LM, Suárez-Farinas M, Sullivan-Whalen M, et al. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010;130(11):2654–2663.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy . Br J Dermatol. 2010;163(6):1282–1290.
   PubMed Web of Science ®Google Scholar
• Lee CH, Wu SB, Hong CH, et al. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14(3):6414–6435.
   PubMed Web of Science ®Google Scholar
• Rácz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol. 2011;131(7):1547–1558.
   PubMed Web of Science ®Google Scholar
• Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000;275(2):1169–1175.
   PubMed Web of Science ®Google Scholar
• Vigne S, Palmer G, Lamacchia C, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011;118(22):5813–5823.
   PubMed Web of Science ®Google Scholar
• Capon F. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526.
   PubMed Web of Science ®Google Scholar
• Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428–2437.
   PubMed Web of Science ®Google Scholar
• Benezeder T, Wolf P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin Immunopathol. 2019;41(6):633–644.
   PubMed Web of Science ®Google Scholar
• El-Hanbuli HM, Dawoud NM, Mahmoud RH. Narrow-band UVB effects on cutaneous vitamin D receptor expression and serum 25-hydroxyvitamin D in generalized vitiligo. Photodermatol Photoimmunol Photomed. 2018;34(3):175–183.
   PubMed Web of Science ®Google Scholar
• Germán B, Wei R, Hener P, et al. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight. 2019;4(2):e123390.
   PubMed Web of Science ®Google Scholar
• Wolf J, Ferris LK. Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569. Expert Opin Ther Pat. 2014;24(4):477–479.
   PubMed Web of Science ®Google Scholar